• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical immunology: The official journal of the Clinical Immunology Society >In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients.
【24h】

In vitro assessment of dendritic cells pulsed with apoptotic tumor cells as a vaccine for ovarian cancer patients.

机译：体外评估用凋亡性肿瘤细胞脉冲刺激的树突状细胞作为卵巢癌患者的疫苗。

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Surgery and chemotherapy are standard treatments in ovarian cancer, but patients have a high rate of relapse. Dendritic cell (DC)-based vaccines are a new treatment option for elimination of residual tumor disease. We aim to explore the feasibility and immunogenicity of DC vaccines pulsed with autologous irradiated tumor cells from ovarian cancer patients. Monocyte-derived DC were generated and pulsed with autologous tumor-derived bodies, matured and subsequently cocultured with autologous lymphocytes. The ability of DC to activate lymphocytes was evaluated by proliferation and IFN-gamma ELISPOT. Induction of tumor cell apoptosis was optimal at 24 h, and DC pulsing optimal at 4 h. Maturation of DC and proliferation of lymphocytes were achieved in 75% of patients tested. Lymphocyte IFN-gamma production increased in response to tumor antigen-pulsed DC. We show the feasibility of preparing individual DC-based vaccines in ovarian cancer patients and the potential for induction of lymphocyte responses.
机译：手术和化学疗法是卵巢癌的标准治疗方法，但患者复发率很高。基于树突细胞（DC）的疫苗是消除残留肿瘤疾病的新治疗选择。我们旨在探讨用卵巢癌患者的自体放射肿瘤细胞脉冲接种DC疫苗的可行性和免疫原性。产生单核细胞衍生的DC，并用自体肿瘤衍生体脉冲，成熟并随后与自体淋巴细胞共培养。通过增殖和IFN-γELISPOT评估DC激活淋巴细胞的能力。肿瘤细胞凋亡的诱导在24 h最佳，而DC脉冲在4 h最佳。在75％的受试患者中，DC的成熟和淋巴细胞的增殖得以实现。响应肿瘤抗原脉冲的DC，淋巴细胞IFN-γ产生增加。我们展示了在卵巢癌患者中制备基于DC的单独疫苗的可行性以及诱导淋巴细胞反应的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号